SURVIVAL AND TOXICITY UPDATE OF THE PHASE 2 TRIAL OF BEVACIZUMAB (BV) IN COMBINATION WITH TEMOZOLOMIDE (TMZ) AND RADIATION THERAPY (RT) FOLLOWED BY BV, TMZ, AND IRINOTECAN (CPT-11) FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) PATIENTS
Publication
, Conference
Desjardins, A; Reardon, DA; Peters, KB; Herndon, JE; Kirkpatrick, JP; Friedman, HS; Vredenburgh, JJ
Published in: NEURO-ONCOLOGY
November 1, 2010
Duke Scholars
Published In
NEURO-ONCOLOGY
ISSN
1522-8517
Publication Date
November 1, 2010
Volume
12
Start / End Page
77 / 77
Location
Hollywood, FL
Publisher
OXFORD UNIV PRESS INC
Conference Name
Advances in Inflammatory Bowel Diseases Crohns and Colitis Foundations National Clinical and Research Conference
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Desjardins, A., Reardon, D. A., Peters, K. B., Herndon, J. E., Kirkpatrick, J. P., Friedman, H. S., & Vredenburgh, J. J. (2010). SURVIVAL AND TOXICITY UPDATE OF THE PHASE 2 TRIAL OF BEVACIZUMAB (BV) IN COMBINATION WITH TEMOZOLOMIDE (TMZ) AND RADIATION THERAPY (RT) FOLLOWED BY BV, TMZ, AND IRINOTECAN (CPT-11) FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) PATIENTS. In NEURO-ONCOLOGY (Vol. 12, pp. 77–77). Hollywood, FL: OXFORD UNIV PRESS INC.
Desjardins, Annick, David A. Reardon, Katherine B. Peters, James E. Herndon, John P. Kirkpatrick, Henry S. Friedman, and James J. Vredenburgh. “SURVIVAL AND TOXICITY UPDATE OF THE PHASE 2 TRIAL OF BEVACIZUMAB (BV) IN COMBINATION WITH TEMOZOLOMIDE (TMZ) AND RADIATION THERAPY (RT) FOLLOWED BY BV, TMZ, AND IRINOTECAN (CPT-11) FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) PATIENTS.” In NEURO-ONCOLOGY, 12:77–77. OXFORD UNIV PRESS INC, 2010.
Desjardins A, Reardon DA, Peters KB, Herndon JE, Kirkpatrick JP, Friedman HS, et al. SURVIVAL AND TOXICITY UPDATE OF THE PHASE 2 TRIAL OF BEVACIZUMAB (BV) IN COMBINATION WITH TEMOZOLOMIDE (TMZ) AND RADIATION THERAPY (RT) FOLLOWED BY BV, TMZ, AND IRINOTECAN (CPT-11) FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) PATIENTS. In: NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2010. p. 77–77.
Desjardins, Annick, et al. “SURVIVAL AND TOXICITY UPDATE OF THE PHASE 2 TRIAL OF BEVACIZUMAB (BV) IN COMBINATION WITH TEMOZOLOMIDE (TMZ) AND RADIATION THERAPY (RT) FOLLOWED BY BV, TMZ, AND IRINOTECAN (CPT-11) FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) PATIENTS.” NEURO-ONCOLOGY, vol. 12, OXFORD UNIV PRESS INC, 2010, pp. 77–77.
Desjardins A, Reardon DA, Peters KB, Herndon JE, Kirkpatrick JP, Friedman HS, Vredenburgh JJ. SURVIVAL AND TOXICITY UPDATE OF THE PHASE 2 TRIAL OF BEVACIZUMAB (BV) IN COMBINATION WITH TEMOZOLOMIDE (TMZ) AND RADIATION THERAPY (RT) FOLLOWED BY BV, TMZ, AND IRINOTECAN (CPT-11) FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) PATIENTS. NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2010. p. 77–77.
Published In
NEURO-ONCOLOGY
ISSN
1522-8517
Publication Date
November 1, 2010
Volume
12
Start / End Page
77 / 77
Location
Hollywood, FL
Publisher
OXFORD UNIV PRESS INC
Conference Name
Advances in Inflammatory Bowel Diseases Crohns and Colitis Foundations National Clinical and Research Conference
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences